LIMR Chemical Genomics Center (LCGC)
![Genomics abstract illustration](/-/media/images/basic-pages/research/limr/technology/lcgc/2023/chemical-genomics-center.jpg?h=440&w=660&la=en&hash=3242A745E0196A92D5AA2D8E142443A4)
About
The LIMR Chemical Genomics Center (LCGC) is housed at the Lankenau Institute for Medical Research (LIMR), founded in 1929 at Lankenau Medical Center. We offer state-of-the-art infrastructure to scientists worldwide for accelerating early-stage pharmaceutical R&D. One of the special technologies is orthogonal pooled screening (OPS). It enables scientists to test large collections of compounds 500% more efficiently to identify first-in-class drug leads for challenging medical indications. A novel application called ultra-HTS for Synergy (uHTSS) provides scientists with unprecedented potential to reveal synergistic drug combinations for "orphan" diseases. Our resources also provide a foundation for innovative public-private partnering initiatives in pharmaceutical R&D.
- Orthogonal Pooled Screening Overview (PDF)
- Combinatorial Screening Overview (PDF)
- SOTA Compound Management with NARS (PDF)
- Open Innovation with DBD2 (PDF)
- LCGC Compound Libraries: Technical Detail (available on request)
Technologies and research services
Overview:
- Rare Chemical Collection—Proprietary library of 104,000 unique compounds filtered for drug-likeness is now available on assay-ready plates in the OPS format.
- Unprecedented efficiency—500% improved efficiency and 80% cost reduction are guaranteed, with zero overhead burden. Ideal for resource-intensive cell assays or assays using expensive reagents.
- Validated Turnkey Systems—Automated compound management and data deconvolution provides structure-activity reports with fast turnaround.
Orthogonal-Pooled Screening (OPS)
Intelligent compound-pooling guarantees successful outcomes while reducing cost, time and overhead by 80%.
- Provides medicinal chemists just-in-time new scaffolds for key decision making on lead drug and backup-candidate development.
- Screens five targets for the equivalent cost and effort of a single screen.
Ultra-HTS for Synergy
New paradigm in combinatorial drug discovery.
- Elegant method to identify unexpected (i.e., patentable) synergistic drug combinations.
- Applicable to branded, generic and OTC drugs. Suitable for pharmaceutical repositioning, ChemAg applications and nutraceutical R&D.
- "Drug combination boxes" are now available representing the pharmacological compendium of FDA-approved drugs and nutraceuticals.
- 15:1 compression = 1500% improved efficiency
- Special combination boxes for "conditioned HTS" (e.g., synthetic-lethal).
- Unprecedented potential for identifying binary and ternary combinations.
Automated Compound Repository
State-of-the-art, automated storage and retrieval system preserves quality of chemical assets and supports focused drug discovery and pharmacophore modeling.
- Innovative robotic repository (issued two U.S. patents) stores and distributes chemical assets — with no freeze-thaw cycling.
- Preserves sample quality indefinitely; optimal for compound management or DNA storage and other biorepository applications.
- Storage and retrieval capacity for 10 million samples with high-throughput pick rates of up to 10,000/day.
- Available at no additional cost to our OPS users, providing access to our unique compound collections and services.
Compound Libraries
The Core FMC Collection of 104,000 drug-like small molecules was the proprietary R&D asset of a top-tier Chem-Ag company.
- First-ever proprietary ChemAg library made available to scientists for pharmaceutical R&D.
- Contains thousands of unique scaffolds not available anywhere else.
- Analysis by HPLC/MS demonstrates the collection meets a high QC/QA benchmark.
- Computationally filtered library considered "drug-like" by "Lipinski Rules" and many other drug-filtering algorithms. An example of the cheminformatic profiling is shown.
LCGC HTS libraries also include these other sets:
- ChemBridge — 100,000 compounds assembled from the 50,000-member DIVERSet™-EXP library, plus the 50,000-compound DIVERSet™-CL library
- Life Chemicals Inc — 50,000 compounds selected to complement overall diversity.
- MicroSource Pharmakon — 1,760 combines the 1,360 drugs in its U.S. drug collection with the 400 drugs from the international drug collection.
- MicroSource Spectrum — ~1,000 bioactive compounds and natural product analogs.
- NCI-Approved Oncology Set — 166 of the most current FDA-approved anticancer drugs.
- Nutraceuticals — ~150 individual neat powders acquired from Sigma, Cayman and other vendors.
- Misc. — ~8,000 compounds acquired from other commercial vendors, primarily ChemDiv and TimTec.
![LIMR Chemical Genomics Center](/-/media/images/basic-pages/research/limr/technology/lcgc/lcgclogo.jpg?h=200&w=200&hash=2061A6BA97CC1E1A2AFF1BC67F581F68)
Contact
Dr. Mel Reichman | 484.476.8230 | [email protected]
LIMR Chemical Genomics Center
100 East Lancaster Avenue
Wynnewood, PA 19096